NS340 Week 3: Using the Evidence - Evidence-Based Practice, Epidemiology, and Disease Control

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/43

flashcard set

Earn XP

Description and Tags

Comprehensive vocabulary flashcards covering Evidence-Based Practice (EBP), study designs, quality appraisal, epidemiology, biostatistics, public health surveillance, and communicable disease management from NS340 Week 3 lecture notes.

44 Terms

1
New cards
<p>Evidence-Based Practice (EBP)</p>

Evidence-Based Practice (EBP)

The integration of the best available research, clinical expertise, and patient or community preferences to guide healthcare decisions.

2
New cards

Barriers to EBP

Barrier

What to look for in a question

Lack of Knowledge

Nurse doesn't know how

Resistance to Change

Nurse doesn't want to change

Implementation Gap

Nurse knows the evidence but doesn't apply it

Limited Resources

Nurse doesn't have the tools or access

Lack of Organizational Support

Leadership doesn't provide support


3
New cards

PICOT

Letter

Meaning

What you're asking

P

Population/Patient/Problem

Who is the patient or population?

I

Intervention

What treatment or action are you considering?

C

Comparison

What are you comparing the intervention to?

O

Outcome

What result do you want?

T

Time

Over what period?


4
New cards

Seven Steps of EBP

Step

Meaning

Simple explanation

0. Cultivate a Spirit of Inquiry

Be curious

Question why things are done a certain way.

1. Ask a PICOT Question

Identify the problem

Develop a focused clinical question.

2. Search for Evidence

Find research

Use databases like PubMed or CINAHL.

3. Critically Appraise Evidence

Evaluate research

Determine whether the evidence is reliable, valid, and relevant.

4. Integrate Evidence

Apply findings

Combine research with clinical expertise and patient preferences to make a practice decision.

5. Evaluate Outcomes

Check results

Determine whether the change improved patient care.

6. Disseminate Outcomes

Share findings

Communicate results with other healthcare professionals.


5
New cards
<p>Hierarchy of Evidence</p>

Hierarchy of Evidence

A ranked pyramid of study designs arranged from strongest to weakest: Level I (Systematic Reviews & Meta-Analyses), Level II (Randomized Controlled Trials), Level III (Controlled Trials without Randomization), Level IV (Case-Control & Cohort Studies), Level V (Systematic Reviews of Qualitative Studies), Level VI (Single Descriptive / Qualitative Studies), and Level VII (Expert Opinion).

6
New cards

Observational Study

A category of study designs where investigators examine relationships or patterns in data by observing subjects without manipulating or assigning exposures.

7
New cards

Experimental Study

A study design where investigators directly control the intervention by assigning exposures and comparing outcomes, serving as the strongest design for causal inference.

8
New cards

Cross-Sectional Study

An observational study design capturing a "snapshot" of exposures and outcomes at a single point in time; best for determining disease prevalence, estimating public health burden, planning, and hypothesis generation, with the limitation that it cannot establish causality.

9
New cards

Case-Control Study

An observational study design that compares subjects with a specific outcome or disease to subjects without the outcome to retrospectively assess prior exposures; best for rare diseases and outbreak investigations, but limited by recall bias and an inability to measure incidence.

10
New cards

Cohort Study

An observational study design that tracks an exposed and unexposed group forward over time to identify who develops the outcome; best for studying common exposures, multiple outcomes, long-term risk assessment, and natural history, but is costly and time-consuming.

11
New cards

Randomized Controlled Trial (RCT)

The gold-standard prospective experimental study design using random assignment to test interventions for causal effect against a comparison group; limited by high financial cost and ethical constraints.

12
New cards

Quasi-Experimental Study

An experimental study design where an intervention is tested without full random assignment, commonly utilized in pragmatic and real-world clinical settings.

13
New cards

AHRQ Appraisal Triad

An evidence appraisal model developed by the Agency for Healthcare Research and Quality evaluating three components: Quality (strength of evidence, study bias, and methodology), Quantity (number of studies, sample sizes, and effect sizes), and Consistency (similarity of findings across studies, alignment of syntheses, and stability over time).

14
New cards

Quality Assurance (QA)

A reactive, backward-looking monitoring process—often led by governmental agencies—designed to watch and evaluate services to confirm established standards are adhered to and correct identified deficiencies.

15
New cards

Quality Improvement (QI)

A proactive, forward-looking process that continuously refines clinical systems, reduces variation in healthcare delivery, enhances patient outcomes, and supports accreditation standards using structured frameworks such as PDSA.

16
New cards
<p>PDSA Cycle</p>

PDSA Cycle

A continuous quality improvement model consisting of Plan (define change, state question, predict outcome, plan test), Do (carry out small-scale test and document observations), Study (analyze results, compare actual against predicted outcomes, identify learning), and Act (adopt, adapt, or abandon the change to make it sustainable or begin another cycle).

17
New cards

Major Accrediting Bodies

External organizations setting operational quality standards: The Joint Commission (hospitals, health systems, behavioral health, home care), PHAB (Public Health Accreditation Board for health departments), CCNE and ACEN (nursing education programs), and CARF, NCQA, and URAC (specialty bodies for rehabilitation, managed care, and healthcare operations).

18
New cards

Community-Based Participatory Research (CBPR)

A collaborative approach where community members are full partners rather than research subjects across all stages (problem identification, study design, data collection, analysis, intervention development, and dissemination), guided by leveraging community strengths, developing local leadership, and generating sustainable interventions.

19
New cards

Wilder's Community-Engagement Research Model

A framework delineating levels of community involvement and associated participant roles: Informed corresponds to Advisor; Involved corresponds to Collaborator; Directed corresponds to Leader.

20
New cards

Epidemiology

The study of how diseases and health-related events occur and spread within populations, and the factors that influence them, centered on investigating Person (who is affected), Place (where it occurs), and Time (when it occurs).

21
New cards

Six Core Functions of Epidemiology

The interconnected operational cycle of epidemiology: Surveillance (continuous monitoring and threat detection), Investigation (inquiry into unusual trends), Analytic Studies (testing exposure-outcome relationships to establish cause), Evaluation (assessing intervention efficacy), Linkages (multidisciplinary partnerships), and Policy Development (translating epidemiological data into health regulations and laws).

22
New cards

Reliability

The precision, consistency, or repeatability of a clinical or epidemiological measurement instrument.

23
New cards

Validity

The degree to which a measurement instrument accurately reflects what it is intended to evaluate, measured specifically through sensitivity and specificity.

24
New cards
<p>Sensitivity</p>

Sensitivity

The true positive rate of a diagnostic tool, representing its ability to correctly identify persons who have the disease; high sensitivity minimizes false negatives.

25
New cards

Specificity

The true negative rate of a diagnostic tool, representing its ability to correctly identify persons who do not have the disease; high specificity minimizes false positives.

26
New cards

Point Prevalence

The proportion of individuals in a population exhibiting a disease at a single specific point in time.

27
New cards

Period Prevalence

The proportion of individuals in a population exhibiting a disease throughout a designated time interval.

28
New cards

Incidence Rate

The rate at which new cases of disease arise in a population at risk over a specified time period: Incidence Rate=Number of new cases occurring during a specified periodNumber of persons at risk during that time period×100,000\text{Incidence Rate} = \frac{\text{Number of new cases occurring during a specified period}}{\text{Number of persons at risk during that time period}} \times 100{,}000.

29
New cards

Crude Mortality Rate

The total proportion of deaths occurring from any cause within a general population over a calendar year: Crude Mortality Rate=Number of deaths occurring in 1 yearMidyear population×100,000\text{Crude Mortality Rate} = \frac{\text{Number of deaths occurring in } 1 \text{ year}}{\text{Midyear population}} \times 100{,}000.

30
New cards

Cause-Specific Mortality Rate

The mortality rate in a general population resulting from a specific disease within a year: Cause-Specific Mortality Rate=Total deaths from a stated cause in 1 yearMidyear population×100,000\text{Cause-Specific Mortality Rate} = \frac{\text{Total deaths from a stated cause in } 1 \text{ year}}{\text{Midyear population}} \times 100{,}000.

31
New cards

Case Fatality Rate

The proportion of diagnosed cases of a specific disease that end in death, indicating the disease's lethality: Case Fatality Rate=Number of deaths from a specific diseaseNumber of cases of the same disease×100\text{Case Fatality Rate} = \frac{\text{Number of deaths from a specific disease}}{\text{Number of cases of the same disease}} \times 100.

32
New cards

Proportionate Mortality

The proportion of all deaths in a given population and time period attributable to a single specific cause: Proportionate Mortality=Number of deaths from a specific cause within a time periodTotal deaths in the same time period×100\text{Proportionate Mortality} = \frac{\text{Number of deaths from a specific cause within a time period}}{\text{Total deaths in the same time period}} \times 100.

33
New cards

Epidemiological Triangle

A model of disease causation requiring an interaction among three components for illness to develop: Agent (virus, bacteria, or fungus), Host (human or animal), and Environment (factors sustaining the agent and host).

34
New cards

Active Immunity

Immunity produced directly by an individual's immune system creating antibodies; acquired either naturally (following recovery from an infection) or artificially (induced via a vaccine).

35
New cards

Passive Immunity

Temporary immunity gained by transferring preformed antibodies from an outside source rather than producing them internally; acquired naturally (maternal-fetal transfer through placenta or breast milk) or artificially (administration of immune globulin/serum).

36
New cards

Endemic vs. Epidemic vs. Pandemic

Patterns of disease frequency: Endemic describes constant baseline presence in a specific group; Epidemic describes an occurrence clearly exceeding normal expectancy in a given community; Pandemic describes an epidemic that has spread across national and continental boundaries.

37
New cards

Natural History of Disease

A timeline depicting the standard clinical progression of a pathological condition from exposure to resolution in the absence of treatment or medical intervention.

38
New cards

Agents of Bioterrorism

Microorganisms or toxins intentionally disseminated to cause disease or death: Anthrax (spores in livestock treated with ciprofloxacin), Plague (flea vector), Botulism (toxin causing paralysis; treated with antitoxin; linked to honey in infants under 11 and canned foods), Smallpox (viral agent eradicated in 19791979), Viral Hemorrhagic Fevers (Ebola, Marburg), and Tularemia ("Rabbit Fever" transmitted via ticks).

39
New cards
<p>Tick Removal Protocol</p>

Tick Removal Protocol

Step 1: Sanitize needle-nose tweezers (not dull or flat) and the bite site; Step 2: Grasp the tick directly on the head as close to the skin as possible; Step 3: Pull slowly and straight upwards to prevent mouthpart breakage.

40
New cards

Measles vs. Rubella

Vaccine-preventable viral exanthems: Measles presents with buccal Koplik spots and a non-blanching facial rash that spreads downwards; Rubella (German Measles) presents with enlarged lymphadenopathy and a pink maculopapular rash initiating on the trunk without coalescence.

41
New cards

Mantoux Tuberculin Skin Test (TST)

An intradermal screening test for tuberculosis where a 5∘–15∘5^{\circ}\text{--}15^{\circ} needle angle injects tuberculin just below the epidermis of the forearm to produce a 6–10 mm6\text{--}10\,\text{mm} wheal; read 48–72 hours48\text{--}72\text{ hours} later by measuring the millimeter diameter of palpable induration rather than erythema.

42
New cards

Directly Observed Therapy (DOT)

A public health adherence strategy where a healthcare professional directly observes a tuberculosis patient swallow each medication dose to prevent non-compliance and drug resistance.

43
New cards

Acquired Immunodeficiency Syndrome (AIDS) Criteria

The clinical diagnosis of advanced HIV defined by an established HIV infection alongside a CD4CD4 T-lymphocyte cell count dropping below 200 cells/mm3200\,\text{cells/mm}^3 or the diagnosis of an AIDS-defining opportunistic illness.

44
New cards

Nationally Notifiable Diseases

A designated group of approximately 120120 infectious diseases (including cholera, botulism, anthrax, gonorrhea, syphilis, rabies, and tuberculosis) that healthcare providers and laboratories are mandated to report by case numbers to the CDC for epidemiological tracking.